ARRDC1 Antibody - Primary antibody, specific to ARRDC1, Rabbit IgG

Cat. No.: Ab089692

GRADE & PURITY Carrier Free, ExactAb™, Validated, 1.0 mg/mL

Application

IF/ICC, WB

Host species

Rabbit

Reactive species

Human, Mouse, Rat

Isotype

Rabbit IgG

Conjugation

Unconjugated

Overview

Rabbit anti Human ARRDC1 Antibody, Polyclonal, could be used for WB, IF/ICC and so on.

Specifications

Product Name

ARRDC1 Antibody - Primary antibody, specific to ARRDC1, Rabbit IgG

Synonyms

ARRD1_HUMAN antibody | ARRDC 1 antibody | ARRDC1 antibody | Arrestin domain containing 1 antibody | Arrestin domain containing protein 1 antibody | Arrestin domain-containing protein 1 antibody | MGC40555 antibody | OTTHUMP00000022707 antibody | OTTHUMP00

Specifications & Purity

ExactAb™, Validated, Carrier Free, 1.0 mg/mL

Biochemical and Physiological Mechanisms

Functions as an adapter recruiting ubiquitin-protein ligases to their specific substrates.Through an ubiquitination-dependent mechanism plays for instance a role in the incorporation of SLC11A2 into extracellular vesicles. More generally, plays a role in

Host species

Rabbit

Specificity

ARRDC1

Immunogen

KLH-conjugated synthetic peptide encompassing a sequence within the center region of human ARRDC1.

Positive Control

WB:HeLa, NIH/3T3 and C6 cell lysates. IF/ICC: MDA-MB-231 cells.

Conjugation

Unconjugated

Grade

Carrier Free, ExactAb™, Validated

Isotype

Rabbit IgG

SDS-PAGE

150 kDa

Purification Method

Immunogen affinity purified

Concentration

1.0 mg/mL

Product Line

biological_products

Storage and Shipping

Form

Liquid

Storage

Store at -20°C,Avoid repeated freezing and thawing

Shipped In

Ice chest + Ice pads

Stability And Storage

Store at 4°C short term (1-2 weeks). Store at -20°C long term (12 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Images

Western Blot: ARRDC1 Antibody (Ab089692)

ARRDC1 Antibody (Ab089692) - Western Blot
All lanes: ARRDC1 Antibody (Ab089692) at 1/2000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/30000 dilution
Predicted band size: 45 kDa
Observed band size: 48 kDa
Exposure time: 86.8 s

IF/ICC: ARRDC1 Antibody (Ab089692)

ARRDC1 Antibody (Ab089692) - IF/ICC
Immunofluorescent analysis of ARRDC1 staining in MDA-MB-231 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with ARRDC1 Antibody (Ab089692) in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).

Application

Application

Dilution info

WB

1/500-1/2000

IF/ICC

1/100-1/500

Associated Targets(Human)

ARRDC1 Tbio Arrestin domain-containing protein 1 (0 Activities)

Discover Target: ARRDC1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

Per non-negotiable rules, only protocols explicitly provided by the product data can be listed as tested. No tested applications, dilutions, or conditions are specified for this item.

Item-specific tested applications:

• Not specified for this item; refer to CoA/Spec Sheet.

General guidance (for planning only; not a claim of validation for this lot):

• WB, IF/ICC, IHC, IP, and ELISA are common antibody applications. Start with standard titration series (e.g., 1:100–1:2,000) and optimize using positive/negative controls for ARRDC1.

For authoritative, lot-specific protocols (recommended dilutions, incubation times, species tested, positive control tissues/cell lines), consult the CoA/Spec Sheet.

Biological Roles

Focus on the target protein ARRDC1 (literature overview; no clinical claims).

• Protein: ARRDC1 (Arrestin domain-containing protein 1)
• Family: Arrestin-domain containing adaptors (ARRDCs), related to alpha-arrestins.
• Cellular localization: Predominantly cytoplasmic and associated with the plasma membrane; implicated in endosomal and microvesicle pathways (literature).
• Molecular function: Adaptor/scaffold protein that recruits components of the ubiquitin/protein trafficking machinery to regulate membrane protein internalization and sorting (e.g., Nedd4 family E3 ligases interactions; literature).
• Biological processes: Involved in clathrin-independent endocytosis, receptor downregulation, and extracellular vesicle (microvesicle) biogenesis by mediating budding from the plasma membrane (literature). Can influence cargo selection into vesicles.
• Pathways and interactions: Interfaces with ESCRT-related processes and ubiquitin-dependent trafficking. Reported to modulate cell surface receptor abundance and to facilitate shedding of ARRDC1-mediated microvesicles (ARMMs) that can transport signaling cargo between cells (literature).
• Expression: Broad expression with tissue-dependent levels; regulation can occur via transcriptional and post-translational mechanisms (literature).

Research implications:

• Antibodies to ARRDC1 enable mapping of protein abundance, localization (IF/IHC), and interaction networks (co-IP), and support studies on extracellular vesicle content. Validate species reactivity and application compatibility of this specific antibody lot via the CoA/Spec Sheet.

Buffer Applications

Antibody performance depends on appropriate buffer composition tailored to the assay. The following are general, literature-based guidelines; verify compatibility with your exact protocol and this Carrier Free antibody.

• Western blot (WB):

  • Transfer/wash buffer: Tris–glycine or CAPS with 0.05–0.1% Tween-20.
  • Blocking: 5% nonfat dry milk or 3–5% BSA in TBS-T/PBS-T; BSA preferred if milk interferes with phospho-epitopes.
  • Primary antibody diluent: Same as blocking buffer but with reduced blocker (e.g., 1–3% BSA) to balance background vs. binding.

• Immunofluorescence (IF)/Immunocytochemistry (ICC):

  • Permeabilization: 0.05–0.3% Triton X-100 or saponin (epitope-dependent).
  • Blocking: 1–5% BSA or serum from secondary host species in PBS/0.05% Tween-20.
  • Mounting media: Aqueous antifade media for fluorescence retention.

• Immunohistochemistry (IHC):

  • Antigen retrieval: Citrate buffer pH 6.0 or Tris–EDTA pH 9.0 (heat-mediated), optimize per tissue/epitope.
  • Blocking/dilution: Similar to IF; include endogenous peroxidase quench if using HRP detection.

• Immunoprecipitation (IP):

  • Lysis buffers: Non-denaturing (e.g., 1% NP-40 or Triton X-100 in TBS) preserve interactions; RIPA for stringent conditions. Include protease/phosphatase inhibitors.

• ELISA:

  • Coating: Carbonate–bicarbonate buffer pH 9.6 or PBS; blocking with BSA/casein.

Item-specific recommended buffers, pH, and dilutions are not specified; consult the CoA/Spec Sheet.

Green Alternatives

While green chemistry primarily targets small-molecule processes, sustainable practices also apply to antibody use.

Greener practice options (general guidance):

• Buffer selection: Prefer phosphate- or HEPES-based aqueous buffers over organic solvent systems. Avoid chlorinated solvents entirely.
• Preservatives: Use minimal effective concentrations of preservatives (e.g., sodium azide) and consider sterile filtration/aliquoting to reduce bioburden rather than relying solely on chemical biocides.
• Waste minimization: Aliquot upon receipt to extend shelf life and reduce disposals from degradation. Use refillable, low-adsorption plasticware where possible.
• Energy savings: Store working aliquots at −20°C as recommended and avoid unnecessary deep-freeze storage when not required. Consolidate freezer space to reduce energy footprint.
• Conjugation chemistry: When labeling, consider aqueous, copper-free click chemistries to reduce metal contamination and post-reaction cleanups.

Comparison (general):

• Carrier-containing formulations vs Carrier Free
  • Carrier Free (this item): Lower background, easier conjugation, reduced protein-waste stream from carriers; requires more careful handling to prevent adsorption and aggregation.
  • With carriers (BSA/gelatin): Improved stability for routine handling but can introduce background and complicate MS or conjugation workflows.

Item-specific environmental certifications or solvent details are not specified; refer to institutional sustainability guidelines for implementation.

Pharmaceutical Uses

This product is provided strictly for research use only and is not intended for human or veterinary diagnostic or therapeutic applications.

Context in pharmaceutical R&D (general, non-clinical):

• Target qualification: Antibodies to ARRDC1 can support preclinical mechanism-of-action studies by monitoring protein expression, subcellular localization, and engagement in trafficking pathways.
• Assay development: Useful as capture/detection reagents in non-GMP analytical assays (e.g., ELISA, Western blot) to characterize cellular models and investigational agents that modulate ARRDC1-related processes.
• Biomarker research: Enables exploratory evaluation of ARRDC1 levels in preclinical samples; not for clinical diagnostics unless validated under appropriate regulatory frameworks.

Formulation/excipient status:

• No pharmacopeial monograph applies to this research antibody. Excipients, preservative content, and endotoxin levels are not specified for this item; refer to the CoA/Spec Sheet if needed for sensitive cell-based assays.

Handling in regulated environments:

• For any use in GLP settings, document lot number, storage conditions, and qualification data (specificity, linearity, precision) under your internal SOPs.
• Do not incorporate into products for administration to humans or animals.

Item-specific compliance/validation claims beyond “Validated” are not provided here; consult the vendor’s documentation for details.

Physical Properties

As an antibody formulation, many classical physicochemical constants (bp/mp, refractive index) are not applicable.

Item-specific properties (this product):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Concentration: Not specified for this item; refer to CoA/Spec Sheet.
• Formulation/excipients: Carrier Free (no added protein carriers such as BSA). Other excipients/salt/buffer: Not specified for this item; refer to CoA/Spec Sheet.
• pH: Not specified for this item; refer to CoA/Spec Sheet.
• Osmolality: Not specified for this item; refer to CoA/Spec Sheet.

General antibody properties (literature, typical):

• Typical IgG molecular mass: ~150 kDa (monomer); F(ab')2 ~110 kDa; Fab ~50 kDa.
• Solubility: Highly soluble in aqueous buffers (e.g., PBS, TBS) over pH ~6.5–8.0; precipitation can occur at extremes of pH/ionic strength or upon repeated freeze–thaw.
• Isoelectric point (pI): Often in the range pH 6–9 depending on sequence and glycosylation.
• Stability: Enhanced by neutral pH, moderate ionic strength (e.g., 150 mM NaCl), and stabilizers such as sugars or inert proteins; this specific item is Carrier Free, so no added protein stabilizer.

Storage and shipping (product data):

• Storage: Store at −20°C; avoid repeated freezing and thawing.
• Shipping: Shipped in ice chest with ice pads to maintain cold chain.

Note: For lot-specific values (concentration, excipients, pH), consult the CoA/Spec Sheet.

Quality & Grades

This item is supplied as Carrier Free, ExactAb™, Validated. The following explains these designations and their practical implications.

Item-specific grade designations (per product data):

• Carrier Free: Formulated without protein carriers (e.g., BSA, gelatin). Advantages:
  • Minimizes background in immunoassays and cell-based work.
  • Compatible with conjugation chemistries (e.g., HRP, fluorophores) without carrier interference.
  • Reduced risk of carrier-derived contaminants in sensitive applications (e.g., MS-based proteomics). Note: Lacks carrier-mediated stabilization; handle gently and consider adding stabilizer in-house if compatible with your application.
• ExactAb™: A performance branding indicating defined, lot-controlled antibody manufacturing and/or sequence-defined reagent (vendor program). Use cases:
  • Enhanced lot-to-lot consistency and reproducibility.
  • Facilitates quantitative assays when paired with defined concentrations. Verify the CoA for details specific to this lot (concentration, sequence, clonality).
• Validated: The antibody has undergone application-specific validation by the manufacturer. However, specific validated applications/conditions are not listed in the provided data. Consult the CoA/Spec Sheet for validated species, applications, and recommended dilutions.

What is not specified for this item:

• Host species, clonality (mono/polyclonal), isotype, purification method, endotoxin level, and precise formulation are not specified; refer to the CoA/Spec Sheet.

Best practices:

• Upon receipt, record lot number and create working aliquots. Confirm validation status in your intended assay (WB, IF, IHC, IP, ELISA) using positive/negative controls.

Reaction & Applications

This section typically covers roles in chemical synthesis; however, ARRDC1 Antibody is a biological affinity reagent, not a small-molecule reactant or catalyst.

• Not typically applicable: The antibody is not used as a solvent or reagent in classical organic reactions.
• Relevant applications instead include immunodetection and capture of ARRDC1 in research workflows (see Application Protocols and Reaction Conditions for practical immunoassay guidance).

Research utility (general, literature):

• Detection/quantification of ARRDC1 by Western blot, ELISA, immunofluorescence, immunohistochemistry, and immunoprecipitation, provided the antibody is validated for those uses.
• Enrichment of ARRDC1-containing complexes for downstream proteomics (e.g., IP followed by LC–MS/MS), ensuring the Carrier Free stock is maintained for optional conjugation or crosslinking.

Please consult the CoA/Spec Sheet for which applications have been validated for this exact item.

Reaction Conditions

This section provides general, literature-based conditions for common immunoassays using primary antibodies. Item-specific, validated conditions for ARRDC1 Antibody are not provided here; consult the CoA/Spec Sheet.

• Western blot (WB):

  • Sample: Denatured lysates (SDS-PAGE). Load 10–40 µg total protein per lane.
  • Primary incubation: 1–16 h at 4–25°C in TBST with 1–3% BSA. Typical starting dilution 1:500–1:2,000 for primary antibodies; optimize empirically.
  • Wash: 3×5–10 min TBST. Secondary per manufacturer instructions.

• Immunofluorescence (IF)/ICC:

  • Fixation: 4% paraformaldehyde (10–15 min) or methanol (−20°C, 5–10 min) depending on epitope.
  • Permeabilization: 0.1% Triton X-100 (5–10 min), as needed.
  • Blocking: 1–5% BSA or 5–10% serum (30–60 min).
  • Primary incubation: 1–2 h RT or overnight at 4°C; start at 1:100–1:500 and optimize.

• Immunohistochemistry (IHC):

  • Antigen retrieval: Citrate pH 6.0 or Tris–EDTA pH 9.0 (HIER) for 10–20 min.
  • Primary incubation: 1 h RT or overnight at 4°C; starting dilution 1:100–1:500.

• Immunoprecipitation (IP):

  • Antibody amount: 1–5 µg antibody per mg lysate protein with Protein A/G beads; rotate 1–4 h at 4°C.

• ELISA:

  • Coating: 0.5–2 µg/mL antigen in carbonate buffer pH 9.6, 2–16 h at 4°C.
  • Detection: Primary antibody 0.1–1 µg/mL or 1:1,000–1:5,000 equivalent dilution.

These are starting points; actual performance must be optimized for ARRDC1 detection using appropriate positive/negative controls.

Safety & Handling

Safety profile for research antibodies is generally favorable, but proper laboratory practices are required.

Item-specific hazard data (from product data):

• GHS classification: Not specified for this item; refer to SDS.
• Signal word: Not specified for this item; refer to SDS.
• H-statements/Pictograms: Not specified for this item; refer to SDS.

General safety guidance (literature/best practice):

• PPE: Wear lab coat, gloves (nitrile), and safety glasses when handling. Avoid ingestion, inhalation of aerosols, or skin/eye contact.
• Biological origin: Antibodies are proteins typically produced in cell culture or animal hosts; handle as a biological reagent of low risk. Follow institutional biosafety procedures.
• Asepsis: To maintain product integrity, work on ice where appropriate and use sterile, low-protein-binding plastics. Avoid microbial contamination.
• Incompatibilities: Avoid extreme pH (<5 or >9), strong oxidizers, organic solvents, and surfactant concentrations that can denature proteins. Do not mix with proteases.
• Freeze–thaw risk: Repeated freeze–thaw can cause aggregation and activity loss; follow Storage & Reconstitution guidance to aliquot upon receipt.
• Spills/first aid: For small spills, absorb with inert material and clean with detergent. For eye/skin contact, rinse with water for ≥15 min; seek medical attention as needed. If inhaled, move to fresh air. If ingested, rinse mouth and seek medical advice. Always defer to SDS.

Waste disposal:

• Dispose of unused material and contaminated consumables as laboratory bio/chemical waste per institutional and local regulations.

Solvent Selection

Antibodies are aqueous biological macromolecules; selection focuses on buffer systems rather than organic solvents.

General buffer selection (literature/practice):

• Working buffers: PBS (10–50 mM phosphate, 150 mM NaCl, pH 7.2–7.6) or TBS (Tris 20–50 mM, 150 mM NaCl, pH 7.4–8.0) are commonly used to maintain isotonicity and stability.
• Additives (if compatible with your assay):
  • Detergents: 0.05–0.1% Tween-20 for wash buffers to reduce nonspecific binding (avoid in conjugation steps).
  • Blocking proteins: 1–5% BSA, casein, or fish gelatin for blocking/dilution in immunoassays. Note: This product is Carrier Free; add blockers only in working buffers, not to the stock if you plan to perform conjugations.
  • Stabilizers: 5–10% glycerol or 0.1–0.5% trehalose can enhance freeze–thaw resistance (verify assay compatibility).
• Preservatives: 0.02–0.05% sodium azide inhibits microbial growth (avoid with HRP or live-cell applications). Not included by default in Carrier Free products unless specified.

When to choose alternatives:

• For metal-sensitive downstream assays (e.g., IMAC-MS), use metal-free buffers and low-salt formulations.
• For live-cell work or functional assays, avoid azide and harsh detergents; use sterile, endotoxin-minimized buffers.

Item-specific solvent details (pH, excipients) are not specified for this product; refer to CoA/Spec Sheet.

Storage & Reconstitution

Follow the product-specific guidance and best practices to maintain antibody integrity.

Item-specific storage/shipping (from product data):

• Storage conditions: Store at −20°C. Avoid repeated freezing and thawing.
• Shipping: Ice chest with ice pads to preserve cold chain.

General handling and reconstitution (literature/best practice):

• Upon receipt: Briefly centrifuge the vial to collect contents. Inspect for turbidity or precipitate.
• Aliquoting: Immediately prepare single-use or short-term aliquots in low-protein-binding tubes to prevent loss and repeated freeze–thaw.
• Reconstitution: If supplied lyophilized (not specified here), reconstitute with sterile, antibody-grade water or buffer (e.g., PBS) to a convenient stock concentration. Mix gently—do not vortex aggressively. Note: This listing does not specify lyophilized vs. liquid; refer to CoA/Spec Sheet.
• Stabilizers: Because this is Carrier Free, consider adding 5–50% glycerol to working aliquots for −20°C storage, and/or 0.02–0.05% sodium azide for microbial control if compatible with your application (avoid azide with HRP and live cells).
• Storage times (typical, literature):
  • Short-term (≤1–2 weeks): 4°C.
  • Medium-term (months): −20°C in aliquots with stabilizer.
  • Long-term (≥6–12 months): −80°C, minimizing freeze–thaw cycles.

Always refer to the CoA/Spec Sheet for lot-specific formulation and reconstitution instructions.

Structure & Identity

Brief overview: This product is an affinity-purified research antibody directed against human ARRDC1 (Arrestin domain-containing protein 1). As an antibody reagent, small-molecule identifiers (CAS, InChIKey, SMILES) are not applicable.

• Product: ARRDC1 Antibody (SKU: Ab089692)
• Category: Antibody reagent for research use only
• Target antigen: ARRDC1 (Arrestin domain-containing protein 1)
• Molecular formula: Not applicable for antibodies; complex glycoprotein mixture (literature)
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Isotype/host/clonality: Not specified for this item; refer to CoA/Spec Sheet.
• Conjugate/label: Carrier Free (no protein carriers such as BSA; see Quality & Grades)

Structural features (general antibody, literature):

• Typical IgG architecture: two heavy chains (~50 kDa each) and two light chains (~25 kDa each) with inter/intrachain disulfides forming a Y-shaped heterotetramer.
• Domains: variable domains (VH/VL) form the antigen-binding sites (paratopes); constant domains (CH1–CH3, CL) mediate stability and Fc interactions (if present; depends on isotype).
• Post-translational features: N-linked glycosylation in Fc (isotype-dependent; literature), which can influence stability and binding to Fc receptors.

Notes on ARRDC1 (literature):

• ARRDC1 is an arrestin-domain containing adaptor implicated in membrane protein trafficking and extracellular vesicle/ microvesicle biogenesis.

Item-specific identity markers (lot/clone/epitope mapping):

• Not specified for this item; refer to CoA/Spec Sheet.

Synthetic Utility

Not typically applicable. ARRDC1 Antibody is a biological affinity reagent and does not serve as a building block, reagent, or catalyst in synthetic organic or organometallic chemistry.

Related laboratory utility (general):

• As an affinity reagent, it can be immobilized on solid supports (e.g., Protein A/G beads or covalent resins) for immunoaffinity enrichment of ARRDC1 and associated complexes prior to analytical characterization.
• Conjugation potential: The Carrier Free format facilitates downstream chemical modification (e.g., NHS–ester fluorophore labeling, maleimide–thiol coupling, click chemistry), enabling creation of custom probes for imaging or capture. Optimize degree of labeling to preserve antigen binding.

For synthetic chemistry needs (solvents, reagents, catalysts), see appropriate small-molecule product categories rather than this antibody listing.

Target Specificity

Only item-specific data from the product listing are reported here.

• Antigen/Target: ARRDC1 (Arrestin domain-containing protein 1)
• Clone/Isotype/Host species: Not specified for this item; refer to CoA/Spec Sheet.
• Epitope mapping/Peptide immunogen: Not specified for this item; refer to CoA/Spec Sheet.
• Species reactivity (human/mouse/rat, etc.): Not specified for this item; refer to CoA/Spec Sheet.
• Cross-reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Validation notes: Labeled as “Validated,” but specific applications/species are not provided in the current data.

General notes (literature, not item-specific): ARRDC1 is an adaptor involved in membrane protein trafficking and microvesicle biogenesis.

For definitive specificity, review the lot-specific CoA/Spec Sheet and perform in-house validation with appropriate controls (knockdown/knockout or overexpression models).